CN116367855A - 特异型性结合成纤维细胞生长因子受体2的拮抗性双互补位抗体及其使用方法 - Google Patents

特异型性结合成纤维细胞生长因子受体2的拮抗性双互补位抗体及其使用方法 Download PDF

Info

Publication number
CN116367855A
CN116367855A CN202180056915.2A CN202180056915A CN116367855A CN 116367855 A CN116367855 A CN 116367855A CN 202180056915 A CN202180056915 A CN 202180056915A CN 116367855 A CN116367855 A CN 116367855A
Authority
CN
China
Prior art keywords
antibody
fgfr2
polypeptide
gal
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180056915.2A
Other languages
English (en)
Chinese (zh)
Inventor
S·查图兰特布特
W·塞勒斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Broad Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Broad Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CN116367855A publication Critical patent/CN116367855A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180056915.2A 2020-06-03 2021-06-02 特异型性结合成纤维细胞生长因子受体2的拮抗性双互补位抗体及其使用方法 Pending CN116367855A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063033975P 2020-06-03 2020-06-03
US63/033,975 2020-06-03
PCT/US2021/035468 WO2021247718A1 (en) 2020-06-03 2021-06-02 Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same

Publications (1)

Publication Number Publication Date
CN116367855A true CN116367855A (zh) 2023-06-30

Family

ID=78829919

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180056915.2A Pending CN116367855A (zh) 2020-06-03 2021-06-02 特异型性结合成纤维细胞生长因子受体2的拮抗性双互补位抗体及其使用方法

Country Status (7)

Country Link
US (1) US20230295308A1 (https=)
EP (1) EP4161566A4 (https=)
JP (1) JP2023528454A (https=)
CN (1) CN116367855A (https=)
AU (1) AU2021284297A1 (https=)
CA (1) CA3185812A1 (https=)
WO (1) WO2021247718A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250148746A (ko) * 2023-01-13 2025-10-14 리제너론 파아마슈티컬스, 인크. Fgfr3 결합 분자 및 그의 사용 방법
CN118852431A (zh) * 2023-04-28 2024-10-29 武汉人福创新药物研发中心有限公司 抗FGFR2b单抗
WO2025070733A1 (en) * 2023-09-29 2025-04-03 Chugai Seiyaku Kabushiki Kaisha Anti-rtk antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (en) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
HUE035700T2 (en) * 2008-11-07 2018-05-28 Galaxy Biotech Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
AR088941A1 (es) * 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
US9498532B2 (en) * 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
AU2014357292B2 (en) * 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
CA2961439A1 (en) * 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
MX2019005552A (es) * 2016-11-14 2019-08-12 Amgen Inc Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.

Also Published As

Publication number Publication date
EP4161566A1 (en) 2023-04-12
CA3185812A1 (en) 2021-12-09
US20230295308A1 (en) 2023-09-21
WO2021247718A1 (en) 2021-12-09
AU2021284297A1 (en) 2023-02-02
JP2023528454A (ja) 2023-07-04
EP4161566A4 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
WO2020107715A1 (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
US11639388B2 (en) CD3 antigen binding fragment and application thereof
KR101434682B1 (ko) 결합 폴리펩티드 및 이들의 용도
WO2020020281A1 (zh) 抗tigit抗体及其用途
CN110462038A (zh) 抗gprc5d抗体和包含所述抗体的分子
TWI596111B (zh) 抗ｅｐｈｂ４抗體及使用該抗體之方法
CN102459346A (zh) 制造异源多聚体分子的方法
CN104271602A (zh) 双特异性抗体
TW201315741A (zh) 結合至包含β－ＫＬＯＴＨＯ及ＦＧＦ受體之複合物之人類抗原結合蛋白
WO2022068854A1 (en) Antibodies targeting human claudin 18.2 and uses thereof
US20180030434A1 (en) Methods of identifying bacteria comprising binding polypeptides
WO2021003739A1 (zh) 四价对称双特异性抗体
CN116367855A (zh) 特异型性结合成纤维细胞生长因子受体2的拮抗性双互补位抗体及其使用方法
KR20250057832A (ko) 갑상선 자극 호르몬 수용체에 결합하는 항체 및 이의 용도
CN115558023A (zh) 抗cd3抗体及其用途
JP2022505144A (ja) Ｈｅｒ２ ｓ３１０ｆ特異的な抗原結合分子
KR20230098335A (ko) 클리핑 비율이 감소된 항원 결합 도메인
CN118146368A (zh) 抗ccr8抗体及其应用
CN119546645A (zh) 特异性结合gucy2c和cd3的抗原结合分子及其医药用途
JP2024540196A (ja) Ｃｃｒ２を標的とする抗体
TW202304991A (zh) 穩定的多重特異性分子及其利用
EP4506361A1 (en) Antibody against c-met and use thereof
WO2026052582A1 (en) Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3
TWI391402B (zh) 抗ｅｐｈｂ４抗體及使用該抗體之方法
WO2026059649A1 (en) Jagged-1 binding agents and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination